Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
AstraZeneca signs drug development deal with biotech Cellectis
03:17am, Wednesday, 01'st Nov 2023
AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas incl
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
03:00am, Wednesday, 01'st Nov 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration A
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript
11:41pm, Friday, 04'th Aug 2023
Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-Founder, CEO & Director Mark Fratt
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
04:30pm, Thursday, 27'th Jul 2023
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
04:30pm, Thursday, 27'th Apr 2023
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
04:30pm, Wednesday, 01'st Mar 2023
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
There's a Lot of Upside For Emerging Gene-Editing Companies
09:16am, Tuesday, 21'st Feb 2023
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter
CLLS Stock: 23.01% Drop Explaination
12:25am, Sunday, 05'th Feb 2023
The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why.
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
04:40pm, Thursday, 01'st Dec 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript
02:29pm, Friday, 04'th Nov 2022
Cellectis S.A. (NASDAQ:CLLS ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Mark Frat
Cellectis to Report Third Quarter 2022 Financial Results
04:37pm, Thursday, 27'th Oct 2022
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
